Chao Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chao Chen has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Yixuan Bao
Center For Precision Cancer Medicine Med‐X Institute The First Affiliated Hospital of Xi'an Jiaotong University Xi'an China
4 shared publications- Dongfeng Dang
School of Chemistry Engineering Research Center of Energy Storage Materials and Devices Xi'an Key Laboratory of Sustainable Polymer Materials Xi'an Jiaotong University Xi'an China
2 shared publications Heng Wang
State Key Laboratory of Organometallic Chemistry Shanghai Institute of Organic Chemistry Shanghai China
2 shared publicationsJianing Yuan
Center For Precision Cancer Medicine Med‐X Institute The First Affiliated Hospital of Xi'an Jiaotong University Xi'an China
2 shared publicationsKai Gao
School of Materials Science and Engineering Xi'an Jiaotong University Xi'an China
2 shared publicationsMeiju Ji
Center for Translational Medicine The First Affiliated Hospital of Xi'an Jiaotong University Xi'an 710061 China
2 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Wiley in Chemistry – A European Journal
- p. e71835
H ‐Aggregated Cationic Isomers to Boost ROS Generation for Photodynamic Therapy
Photodynamic therapy (PDT) has become a burgeoning alternative modality in clinics to treat cancer, and photosensitizers are the critical components for PDT. Herein, considering that the radiative transition from the S 1 to S 0 energy states in H ‐aggregates is symmetry‐forbidden, we proposed that H ‐aggregates were more prone to undergo intersystem crossing (ISC), thereby generating a photodynamic effect. Based on this hypothesis, we have successfully designed and synthesized a pair of isomers with planar structure, 2‐IVQ and 4‐IVQ, to seek for an efficient sensitizer working on H ‐aggregation mechanism. 2‐IVQ tends to form H ‐aggregates more readily, and the formation of H ‐aggregates at high concentrations actually enables effective generation of the photodynamic effect. Interestingly, at low concentrations, 2‐IVQ exhibits a weaker photodynamic effect compared to 4‐IVQ, which further supports the formation of H ‐aggregates in 2‐IVQ at high concentrations. Concentrated in mitochondria of cancer cells, tightly H ‐aggregated 2‐IVQ showed faster ROS generation that induced cell apoptosis, and could self‐report entire PDT process by visualizing the dyeing position change from mitochondria to nucleolus. In addition, 2‐IVQ had a substantial antitumor effect in H460 tumor bearing mice. This work provides a new strategy to promote the ISC for constructing effective phototheranostic reagents based on H ‐aggregation mechanism.
- 30 October 2026
- Published by Wiley in Chemistry – A European Journal
- p. e71835
Open AccessH ‐Aggregated Cationic Isomers to Boost ROS Generation for Photodynamic Therapy
Photodynamic therapy (PDT) has become a burgeoning alternative modality in clinics to treat cancer, and photosensitizers are the critical components for PDT. Herein, considering that the radiative transition from the S 1 to S 0 energy states in H ‐aggregates is symmetry‐forbidden, we proposed that H ‐aggregates were more prone to undergo intersystem crossing (ISC), thereby generating a photodynamic effect. Based on this hypothesis, we have successfully designed and synthesized a pair of isomers with planar structure, 2‐IVQ and 4‐IVQ, to seek for an efficient sensitizer working on H ‐aggregation mechanism. 2‐IVQ tends to form H ‐aggregates more readily, and the formation of H ‐aggregates at high concentrations actually enables effective generation of the photodynamic effect. Interestingly, at low concentrations, 2‐IVQ exhibits a weaker photodynamic effect compared to 4‐IVQ, which further supports the formation of H ‐aggregates in 2‐IVQ at high concentrations. Concentrated in mitochondria of cancer cells, tightly H ‐aggregated 2‐IVQ showed faster ROS generation that induced cell apoptosis, and could self‐report entire PDT process by visualizing the dyeing position change from mitochondria to nucleolus. In addition, 2‐IVQ had a substantial antitumor effect in H460 tumor bearing mice. This work provides a new strategy to promote the ISC for constructing effective phototheranostic reagents based on H ‐aggregation mechanism.
- Open Access
GSH‐Depleted Platinum(II) Metallacycles to Turn On the NIR Emission in Boosting Synergistic Cancer Therapy
Agents to combine functions simultaneously are highly needed but still challenging in synergistic therapy. Particularly, capabilities to deplete glutathione (GSH) in tumors and monitor their process are also important. Therefore, platinum(II) metallacycles are prepared by using aggregation‐induced emission active ligands. Despite their similar structures, high emission for Mh1 is obtained (PLQY = 49.2%) in solids, but a PLQY of only 6.8% is recorded for Mh2. NIR emission in Mh2 can be turned‐on in depleting GSH by releasing emissive ligands. Also, both type I and type II reactive oxygen species (ROS) are obtained in Mh2 nanoparticles. Due to the depletion of GSH and generation of ROS, oxidative stress in immunogenic cell death can be induced. By combining chemotherapy and photoimmunotherapy, synergistic therapy in vivo is obtained for Mh2‐NPs to well inhibit the tumor growth, also showing antitumor immune effects in distant tumors. The work here provides some guidelines in designing the multi‐functional agents, showing the great potentials in efficient cancer therapy.
Open AccessGSH‐Depleted Platinum(II) Metallacycles to Turn On the NIR Emission in Boosting Synergistic Cancer Therapy
Agents to combine functions simultaneously are highly needed but still challenging in synergistic therapy. Particularly, capabilities to deplete glutathione (GSH) in tumors and monitor their process are also important. Therefore, platinum(II) metallacycles are prepared by using aggregation‐induced emission active ligands. Despite their similar structures, high emission for Mh1 is obtained (PLQY = 49.2%) in solids, but a PLQY of only 6.8% is recorded for Mh2. NIR emission in Mh2 can be turned‐on in depleting GSH by releasing emissive ligands. Also, both type I and type II reactive oxygen species (ROS) are obtained in Mh2 nanoparticles. Due to the depletion of GSH and generation of ROS, oxidative stress in immunogenic cell death can be induced. By combining chemotherapy and photoimmunotherapy, synergistic therapy in vivo is obtained for Mh2‐NPs to well inhibit the tumor growth, also showing antitumor immune effects in distant tumors. The work here provides some guidelines in designing the multi‐functional agents, showing the great potentials in efficient cancer therapy.
- Open Access
Mitochondria‐Targeted AIE Materials for Oxidative Stress‐Mediated Cancer Therapy and Beyond
Mitochondria‐targeted aggregation‐induced emission (AIE) materials have emerged as promising candidates for precision medicine by enabling the controllable induction of oxidative stress within mitochondria. Yet, a comprehensive overview of the antitumor and other biological effects resulting from such oxidative stress remains lacking. This review summarizes the roles of both excessive and moderate oxidative stress triggered by mitochondria‐targeted AIE materials across diverse applications, including: (1) direct induction of various forms of cancer cell death and degradation of cancer‐associated proteins; (2) synergistic enhancement of chemo‐, radio‐, immune‐, and other therapies; and (3) treatments beyond cancer. In addition, the challenges and key issues limiting their broader application are discussed. This review highlights the therapeutic potential of controllably induced oxidative stress by mitochondria‐targeted AIE materials, aiming to accelerate their development for precise disease intervention and biological regulation.
Open AccessMitochondria‐Targeted AIE Materials for Oxidative Stress‐Mediated Cancer Therapy and Beyond
Mitochondria‐targeted aggregation‐induced emission (AIE) materials have emerged as promising candidates for precision medicine by enabling the controllable induction of oxidative stress within mitochondria. Yet, a comprehensive overview of the antitumor and other biological effects resulting from such oxidative stress remains lacking. This review summarizes the roles of both excessive and moderate oxidative stress triggered by mitochondria‐targeted AIE materials across diverse applications, including: (1) direct induction of various forms of cancer cell death and degradation of cancer‐associated proteins; (2) synergistic enhancement of chemo‐, radio‐, immune‐, and other therapies; and (3) treatments beyond cancer. In addition, the challenges and key issues limiting their broader application are discussed. This review highlights the therapeutic potential of controllably induced oxidative stress by mitochondria‐targeted AIE materials, aiming to accelerate their development for precise disease intervention and biological regulation.
- 1 April 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (7) , 7780-7791
Highly Emissive Platinum(II) Metallacage in the Near-Infrared Region for Synergistic Chemo-Photodynamic Therapy
Highly emissive metallacages that generate reactive oxygen species (ROS) are important to synergistic cancer therapy, but it is still challenging to balance the emission and phototheranostic properties. Herein, a metallacage of DTPABT-Mc is prepared. It is observed that emission in the near-infrared region from 600 to 1000 nm with a high photoluminescence quantum yield value of 7.92% in solids is recorded for DTPABT-Mc. In addition, the ability to produce both type I and type II ROS under light irradiation is also observed, leading to potential application in photodynamic therapy (PDT) and chemotherapy. After that, 4T1@DTPABT-Mc-NPs, covering DTPABT-Mc nanoparticles with 4T1 cell membranes, are prepared to enhance their tumor-targeting ability. This finally results in effective therapeutic performance in vivo, effectively inhibiting tumor growth. These results suggest that DTPABT-Mc-NPs exhibit excellent synergistic therapeutic effects by combining PDT and chemotherapy, providing new ideas to design agents for diagnosis and therapy in the future.
- 1 April 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (7) , 7780-7791
Highly Emissive Platinum(II) Metallacage in the Near-Infrared Region for Synergistic Chemo-Photodynamic Therapy
Highly emissive metallacages that generate reactive oxygen species (ROS) are important to synergistic cancer therapy, but it is still challenging to balance the emission and phototheranostic properties. Herein, a metallacage of DTPABT-Mc is prepared. It is observed that emission in the near-infrared region from 600 to 1000 nm with a high photoluminescence quantum yield value of 7.92% in solids is recorded for DTPABT-Mc. In addition, the ability to produce both type I and type II ROS under light irradiation is also observed, leading to potential application in photodynamic therapy (PDT) and chemotherapy. After that, 4T1@DTPABT-Mc-NPs, covering DTPABT-Mc nanoparticles with 4T1 cell membranes, are prepared to enhance their tumor-targeting ability. This finally results in effective therapeutic performance in vivo, effectively inhibiting tumor growth. These results suggest that DTPABT-Mc-NPs exhibit excellent synergistic therapeutic effects by combining PDT and chemotherapy, providing new ideas to design agents for diagnosis and therapy in the future.
- 16 January 2025
- Published by Wiley in Advanced Functional Materials
- Vol. 35 (7)
Highly Efficient and Universal Degradation of PD‐L1 via Mitochondrial Oxidative Stress Evoked by Cationic AIE‐Active Photosensitizers for Cancer Immunotherapy
The blockade of interactions between programmed death‐ligand 1 (PD‐L1) on cancer cell surfaces and programmed cell death‐1 (PD‐1) receptors on T cells is a crucial strategy in cancer immunotherapy. However, the continuous replenishment of PD‐L1 from intracellular stores presents a significant challenge that undermines therapeutic efficacy. Therefore, effective downregulation of intracellular PD‐L1 is essential for improving treatment outcomes. In this study, a novel approach that utilizes mitochondrial oxidative stress to achieve highly efficient and universal PD‐L1 degradation is presented. A cationic aggregation‐induced emission‐active photosensitizer, DPA‐B‐YP+, which generates reactive oxygen species (ROS) upon light activation to induce mitochondrial oxidative stress on demand is developed. Compared to traditional high‐performance PD‐L1 degraders such as metformin and berberine, ROS‐induced mitochondrial stress by DPA‐B‐YP+ demonstrates superior efficiency and broader applicability in PD‐L1 degradation across various tumor types. Mechanistic studies reveal that PD‐L1 degradation by DPA‐B‐YP+ occurs via the AMPK‐ubiquitination pathway. Furthermore, in a murine immunogenic “cold” tumor model, DPA‐B‐YP+ effectively degrades PD‐L1 and significantly enhances CD8+ T cell‐mediated immune responses upon light activation, without the need for additional drugs or immune adjuvants. These findings present a novel approach and material for PD‐L1 degradation, contributing to advancements in cancer immunotherapy.
- 16 January 2025
- Published by Wiley in Advanced Functional Materials
- Vol. 35 (7)
Highly Efficient and Universal Degradation of PD‐L1 via Mitochondrial Oxidative Stress Evoked by Cationic AIE‐Active Photosensitizers for Cancer Immunotherapy
The blockade of interactions between programmed death‐ligand 1 (PD‐L1) on cancer cell surfaces and programmed cell death‐1 (PD‐1) receptors on T cells is a crucial strategy in cancer immunotherapy. However, the continuous replenishment of PD‐L1 from intracellular stores presents a significant challenge that undermines therapeutic efficacy. Therefore, effective downregulation of intracellular PD‐L1 is essential for improving treatment outcomes. In this study, a novel approach that utilizes mitochondrial oxidative stress to achieve highly efficient and universal PD‐L1 degradation is presented. A cationic aggregation‐induced emission‐active photosensitizer, DPA‐B‐YP+, which generates reactive oxygen species (ROS) upon light activation to induce mitochondrial oxidative stress on demand is developed. Compared to traditional high‐performance PD‐L1 degraders such as metformin and berberine, ROS‐induced mitochondrial stress by DPA‐B‐YP+ demonstrates superior efficiency and broader applicability in PD‐L1 degradation across various tumor types. Mechanistic studies reveal that PD‐L1 degradation by DPA‐B‐YP+ occurs via the AMPK‐ubiquitination pathway. Furthermore, in a murine immunogenic “cold” tumor model, DPA‐B‐YP+ effectively degrades PD‐L1 and significantly enhances CD8+ T cell‐mediated immune responses upon light activation, without the need for additional drugs or immune adjuvants. These findings present a novel approach and material for PD‐L1 degradation, contributing to advancements in cancer immunotherapy.
- 1 January 2025
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 32 (2) , 380-395
Amplifying Radiotherapy by Evoking Mitochondrial Oxidative Stress using a High-performance Aggregation-induced Emission Sonosensitizer
Introduction: Developing effective methods to enhance tumor radiosensitivity is crucial for improving the therapeutic efficacy of radiotherapy (RT). Due to its deep tissue penetration, excellent safety profile, and precise controllability, sonosensitizer-based sonodynamic therapy (SDT) has recently garnered significant attention as a promising combined approach with RT. Methods: However, the limited reactive oxygen species (ROS) generation ability in the aggregated state and the absence of specific organelle targeting in sonosensitizers hinder their potential to augment RT. This study introduces a fundamental principle guiding the design of high-performance sonosensitizers employed in the aggregated state. Building upon these principles, we develop a mitochondria-targeted sonosensitizer molecule (TCSVP) with aggregation- induced emission (AIE) characteristics by organic synthesis. Then, we demonstrate the abilities of TCSVP to target mitochondria and produce ROS under ultrasound in H460 cancer cells using confocal laser scanning microscopy (CLSM) and fluorescence microscopy. Subsequently, we examine the effectiveness of enhancing tumor radiosensitivity by utilizing TCSVP and ultrasound in both H460 cells and H460 and 4T1 tumor-bearing mice. Results: The results indicate that evoking non-lethal mitochondrial oxidative stress in tumors by TCSVP under ultrasound stimulation can significantly improve tumor radiosensitivity (p <0.05). Additionally, the in vivo safety profile of TCSVP is thoroughly confirmed by histopathological analysis. Conclusion: This work proposes strategies for designing efficient sonosensitizers and underscores that evoking non-lethal mitochondrial oxidative stress is an effective method to enhance tumor radiosensitivity.
- 1 January 2025
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 32 (2) , 380-395
Amplifying Radiotherapy by Evoking Mitochondrial Oxidative Stress using a High-performance Aggregation-induced Emission Sonosensitizer
Introduction: Developing effective methods to enhance tumor radiosensitivity is crucial for improving the therapeutic efficacy of radiotherapy (RT). Due to its deep tissue penetration, excellent safety profile, and precise controllability, sonosensitizer-based sonodynamic therapy (SDT) has recently garnered significant attention as a promising combined approach with RT. Methods: However, the limited reactive oxygen species (ROS) generation ability in the aggregated state and the absence of specific organelle targeting in sonosensitizers hinder their potential to augment RT. This study introduces a fundamental principle guiding the design of high-performance sonosensitizers employed in the aggregated state. Building upon these principles, we develop a mitochondria-targeted sonosensitizer molecule (TCSVP) with aggregation- induced emission (AIE) characteristics by organic synthesis. Then, we demonstrate the abilities of TCSVP to target mitochondria and produce ROS under ultrasound in H460 cancer cells using confocal laser scanning microscopy (CLSM) and fluorescence microscopy. Subsequently, we examine the effectiveness of enhancing tumor radiosensitivity by utilizing TCSVP and ultrasound in both H460 cells and H460 and 4T1 tumor-bearing mice. Results: The results indicate that evoking non-lethal mitochondrial oxidative stress in tumors by TCSVP under ultrasound stimulation can significantly improve tumor radiosensitivity (p <0.05). Additionally, the in vivo safety profile of TCSVP is thoroughly confirmed by histopathological analysis. Conclusion: This work proposes strategies for designing efficient sonosensitizers and underscores that evoking non-lethal mitochondrial oxidative stress is an effective method to enhance tumor radiosensitivity.
- 1 October 2021
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 51, e140-e141
TU83. COMPARING GENE EXPRESSION CHANGES IN BLOOD AND BRAIN OF SCHIZOPHRENIA
- 1 October 2021
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 51, e140-e141
TU83. COMPARING GENE EXPRESSION CHANGES IN BLOOD AND BRAIN OF SCHIZOPHRENIA
- Open Access
- 1 January 2019
- Published by Atlantis Press SARL
Short-term Urban Rail Transit Passenger Flow Forecasting Based on Empirical Mode Decomposition and LSTM
- 1 January 2019
- Published by Atlantis Press SARL
Open AccessShort-term Urban Rail Transit Passenger Flow Forecasting Based on Empirical Mode Decomposition and LSTM